Adamis Pharmaceuticals Corporation Stock Price, News & Analysis (NASDAQ:ADMP)

$4.20 0.15 (3.70 %)
(As of 11/24/2017 02:38 AM ET)
Previous Close$4.05
Today's Range$4.00 - $4.20
52-Week Range$2.55 - $6.45
Volume413,048 shs
Average Volume719,623 shs
Market Capitalization$135.22 million
P/E RatioN/A
Dividend YieldN/A
Beta0.48

About Adamis Pharmaceuticals Corporation (NASDAQ:ADMP)

Adamis Pharmaceuticals Corporation logoAdamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company's product portfolio includes specialty pharmaceutical products, such as Epinephrine pre-filled syringe (PFS), APC-5000 dry powder inhaler (DPI), APC-1000 and APC-2000, and biotechnology products, such as TeloB-VAX (vaccine), APC-100, APC-200 and APC-300. The Company's lead product candidate, the Epinephrine Injection USP 1:1000 0.3 milligram Pre-filled Single Dose Syringe, or the Epinephrine PFS, is a pre-filled syringe designed to deliver a premeasured 0.3 milligrams dose of epinephrine for the treatment of anaphylaxis. The Company also has licensed vaccine technology called somatic transgene immunization (STI) technology.

Receive ADMP News and Ratings via Email

Sign-up to receive the latest news and ratings for ADMP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ADMP
CUSIPN/A
Phone858-997-2400

Debt

Debt-to-Equity Ratio0.06%
Current Ratio3.93%
Quick Ratio3.79%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$6.47 million
Price / Sales21.68
Cash FlowN/A
Price / CashN/A
Book Value$1.38 per share
Price / Book3.04

Profitability

Trailing EPSN/A
Net Income$-19,430,000.00
Net Margins-143.15%
Return on Equity-57.74%
Return on Assets-42.37%

Miscellaneous

Employees16
Outstanding Shares33,390,000

Frequently Asked Questions for Adamis Pharmaceuticals Corporation (NASDAQ:ADMP)

What is Adamis Pharmaceuticals Corporation's stock symbol?

Adamis Pharmaceuticals Corporation trades on the NASDAQ under the ticker symbol "ADMP."

How were Adamis Pharmaceuticals Corporation's earnings last quarter?

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) posted its quarterly earnings results on Monday, November, 14th. The specialty pharmaceutical company reported ($0.41) earnings per share for the quarter, topping analysts' consensus estimates of ($0.48) by $0.07. The specialty pharmaceutical company had revenue of $2.08 million for the quarter. Adamis Pharmaceuticals Corporation had a negative return on equity of 57.74% and a negative net margin of 143.15%. View Adamis Pharmaceuticals Corporation's Earnings History.

When will Adamis Pharmaceuticals Corporation make its next earnings announcement?

Adamis Pharmaceuticals Corporation is scheduled to release their next quarterly earnings announcement on Monday, November, 27th 2017. View Earnings Estimates for Adamis Pharmaceuticals Corporation.

Where is Adamis Pharmaceuticals Corporation's stock going? Where will Adamis Pharmaceuticals Corporation's stock price be in 2017?

3 analysts have issued 12 month target prices for Adamis Pharmaceuticals Corporation's stock. Their predictions range from $7.00 to $13.00. On average, they anticipate Adamis Pharmaceuticals Corporation's share price to reach $10.00 in the next year. View Analyst Ratings for Adamis Pharmaceuticals Corporation.

What are Wall Street analysts saying about Adamis Pharmaceuticals Corporation stock?

Here are some recent quotes from research analysts about Adamis Pharmaceuticals Corporation stock:

  • 1. According to Zacks Investment Research, "Adamis Pharmaceuticals Corporation, formerly Cellegy Pharmaceuticals, Inc., is a specialty pharmaceutical company engaged engages in the research, development, and commercialization of prescription medicines for the treatment of viral infections. Adamis Pharmaceuticals is composed of two wholly owned subsidiaries, Adamis Labs and Adamis Viral Therapies. Adamis Labs is a commercial stage specialty pharmaceutical company targeting high-prescribing physicians in the allergy, respiratory and pediatric medicine market segments. To complement and add to the sales efforts of Adamis Labs, Adamis Viral Therapies is focused on the development of patented, highly-valued proprietary vaccine technology that Adamis believes has the potential to prevent or treat infections such as influenza or chronic hepatitis. Adamis also provides packaging for pharmaceutical and nutraceutical products. The company is headquartered in Del Mar, California. " (11/20/2017)
  • 2. Maxim Group analysts commented, "Adamis reported the second quarter (10Q) 2017, with revenues of $3.8M and a net loss of $4.9M for the period. The 10Q shows that the company ended the period with $11.8M in cash. However, our understanding is that the company now has close to $25M in cash as a result of cash brought in from warrant holders associated with the last financing." (8/21/2017)

Who are some of Adamis Pharmaceuticals Corporation's key competitors?

Who are Adamis Pharmaceuticals Corporation's key executives?

Adamis Pharmaceuticals Corporation's management team includes the folowing people:

  • Richard C. Williams, Independent Chairman of the Board (Age 71)
  • Dennis J. Carlo Ph.D., President, Chief Executive Officer, Director (Age 71)
  • Robert O. Hopkins, Chief Financial Officer, Vice President - Finance (Age 54)
  • David J. Marguglio, Senior Vice President - Corporate Development, Director (Age 44)
  • Karen K. Daniels, Vice President - Operations (Age 62)
  • Gus Fernandez Pharm.D., Vice President - Commercial Operations (Age 54)
  • Thomas Moll Ph.D., Vice President - Research (Age 49)
  • William Charles Denby III, Independent Director (Age 60)
  • Robert B. Rothermel, Independent Director (Age 71)

Who owns Adamis Pharmaceuticals Corporation stock?

Adamis Pharmaceuticals Corporation's stock is owned by a number of of institutional and retail investors. Top institutional investors include ESES HOLDINGS (FZE) (4.90%), EAM Investors LLC (1.19%), Granite Investment Partners LLC (0.28%), Advisor Group Inc. (0.18%) and Bank of New York Mellon Corp (0.09%). View Institutional Ownership Trends for Adamis Pharmaceuticals Corporation.

Who bought Adamis Pharmaceuticals Corporation stock? Who is buying Adamis Pharmaceuticals Corporation stock?

Adamis Pharmaceuticals Corporation's stock was purchased by a variety of institutional investors in the last quarter, including EAM Investors LLC, Granite Investment Partners LLC, Advisor Group Inc. and Bank of New York Mellon Corp. View Insider Buying and Selling for Adamis Pharmaceuticals Corporation.

How do I buy Adamis Pharmaceuticals Corporation stock?

Shares of Adamis Pharmaceuticals Corporation can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Adamis Pharmaceuticals Corporation's stock price today?

One share of Adamis Pharmaceuticals Corporation stock can currently be purchased for approximately $4.20.

How big of a company is Adamis Pharmaceuticals Corporation?

Adamis Pharmaceuticals Corporation has a market capitalization of $135.22 million and generates $6.47 million in revenue each year. Adamis Pharmaceuticals Corporation employs 16 workers across the globe.

How can I contact Adamis Pharmaceuticals Corporation?

Adamis Pharmaceuticals Corporation's mailing address is 11682 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The specialty pharmaceutical company can be reached via phone at 858-997-2400 or via email at [email protected]


MarketBeat Community Rating for Adamis Pharmaceuticals Corporation (ADMP)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  136 (Vote Outperform)
Underperform Votes:  65 (Vote Underperform)
Total Votes:  201
MarketBeat's community ratings are surveys of what our community members think about Adamis Pharmaceuticals Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Adamis Pharmaceuticals Corporation (NASDAQ:ADMP)

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldBuyBuyBuy
Consensus Rating Score: 2.202.502.673.00
Ratings Breakdown: 2 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $10.00$9.83$9.00$7.50
Price Target Upside: 138.10% upside90.02% upside95.65% upside68.54% upside

Consensus Price Target History for Adamis Pharmaceuticals Corporation (NASDAQ:ADMP)

Price Target History for Adamis Pharmaceuticals Corporation (NASDAQ:ADMP)

Analysts' Ratings History for Adamis Pharmaceuticals Corporation (NASDAQ:ADMP)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/15/2017B. RileySet Price TargetBuy$10.00N/AView Rating Details
9/12/2017Raymond James Financial, Inc.Initiated CoverageOutperform$7.00HighView Rating Details
8/21/2017Maxim GroupReiterated RatingBuy$13.00HighView Rating Details
(Data available from 11/25/2015 forward)

Earnings

Earnings History and Estimates Chart for Adamis Pharmaceuticals Corporation (NASDAQ:ADMP)

Earnings by Quarter for Adamis Pharmaceuticals Corporation (NASDAQ:ADMP)

Earnings History by Quarter for Adamis Pharmaceuticals Corporation (NASDAQ ADMP)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/27/2017        
11/14/2016Q3 2016($0.48)($0.41)$2.08 millionViewN/AView Earnings Details
8/15/2016Q2($0.37)$1.93 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Adamis Pharmaceuticals Corporation (NASDAQ:ADMP)
2017 EPS Consensus Estimate: ($0.67)
2018 EPS Consensus Estimate: ($0.60)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.21)($0.21)($0.21)
Q2 20171($0.16)($0.16)($0.16)
Q3 20171($0.16)($0.16)($0.16)
Q4 20171($0.14)($0.14)($0.14)
Q1 20181($0.14)($0.14)($0.14)
Q2 20181($0.13)($0.13)($0.13)
Q3 20181($0.17)($0.17)($0.17)
Q4 20181($0.16)($0.16)($0.16)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Adamis Pharmaceuticals Corporation (NASDAQ:ADMP)

No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Adamis Pharmaceuticals Corporation (NASDAQ ADMP)

Insider Ownership Percentage: 9.60%
Institutional Ownership Percentage: 9.93%
Insider Trades by Quarter for Adamis Pharmaceuticals Corporation (NASDAQ:ADMP)
Insider Trades by Quarter for Adamis Pharmaceuticals Corporation (NASDAQ:ADMP)

Insider Trades by Quarter for Adamis Pharmaceuticals Corporation (NASDAQ ADMP)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/2/2016David J MarguglioVPSell700$9.00$6,300.00View SEC Filing  
5/16/2016David J MarguglioSVPSell4,000$8.08$32,320.00View SEC Filing  
5/9/2016David J MarguglioSVPSell4,860$10.00$48,600.00View SEC Filing  
5/4/2016David J MarguglioSVPSell4,860$9.17$44,566.20View SEC Filing  
5/3/2016David J MarguglioSVPSell1,140$9.00$10,260.00View SEC Filing  
4/14/2016David J MarguglioSVPSell12,000$7.52$90,240.00View SEC Filing  
8/14/2015Robert B RothermelDirectorBuy7,000$3.33$23,310.00View SEC Filing  
4/20/2015David J MarguglioSVPSell200$5.00$1,000.00View SEC Filing  
4/14/2015David J MarguglioSVPSell2,200$5.01$11,022.00View SEC Filing  
3/4/2015David J MarguglioSVPSell11,800$7.09$83,662.00View SEC Filing  
3/2/2015David J MarguglioSVPSell7,000$6.45$45,150.00View SEC Filing  
2/13/2015Ahmed Shayan Fazlur RahmanMajor ShareholderSell12,076$6.41$77,407.16View SEC Filing  
2/12/2015Ahmed Shayan Fazlur RahmanMajor ShareholderSell38,000$6.40$243,200.00View SEC Filing  
2/3/2015Ahmed Shayan Fazlur RahmanMajor ShareholderSell30,000$6.75$202,500.00View SEC Filing  
1/5/2015David J MarguglioVPSell7,000$6.18$43,260.00View SEC Filing  
12/30/2014David J MarguglioSVPSell12,228$6.09$74,468.52View SEC Filing  
12/29/2014David J MarguglioVPSell772$6.00$4,632.00View SEC Filing  
12/12/2014David J MarguglioSVPSell4,000$5.18$20,720.00View SEC Filing  
9/2/2014William C DenbyDirectorBuy2,500$5.06$12,650.00View SEC Filing  
8/29/2014Robert B RothermelDirectorBuy5,500$4.03$22,165.00View SEC Filing  
6/2/2014David J MarguglioSVPSell4,000$5.56$22,240.00View SEC Filing  
8/14/2013Ahmed Shayan Fazlur RahmanMajor ShareholderSell7,015$0.57$3,998.55View SEC Filing  
8/7/2013Ahmed Shayan Fazlur RahmanMajor ShareholderSell40,000$0.56$22,400.00View SEC Filing  
8/2/2013Ahmed Shayan Fazlur RahmanMajor ShareholderSell67,960$0.57$38,737.20View SEC Filing  
7/30/2013Ahmed Shayan Fazlur RahmanMajor ShareholderSell10,328$0.56$5,783.68View SEC Filing  
7/26/2013Ahmed Shayan Fazlur RahmanMajor ShareholderSell95,000$0.56$53,200.00View SEC Filing  
7/23/2013Ahmed Shayan Fazlur RahmanMajor ShareholderSell141,224$0.57$80,497.68View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Adamis Pharmaceuticals Corporation (NASDAQ ADMP)

Source:
DateHeadline
Comparing Histogenics Corporation (HSGX) & Adamis Pharmaceuticals Corporation (ADMP)Comparing Histogenics Corporation (HSGX) & Adamis Pharmaceuticals Corporation (ADMP)
www.americanbankingnews.com - November 21 at 5:12 AM
Adamis Pharmaceuticals Corporation (ADMP) Stock Rating Lowered by Zacks Investment ResearchAdamis Pharmaceuticals Corporation (ADMP) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - November 21 at 12:52 AM
ETFs with exposure to Adamis Pharmaceuticals Corp. : November 20, 2017ETFs with exposure to Adamis Pharmaceuticals Corp. : November 20, 2017
finance.yahoo.com - November 20 at 5:01 PM
B. Riley Analysts Give Adamis Pharmaceuticals Corporation (ADMP) a $10.00 Price TargetB. Riley Analysts Give Adamis Pharmaceuticals Corporation (ADMP) a $10.00 Price Target
www.americanbankingnews.com - November 19 at 10:58 PM
Adamis Pharmaceuticals Corporation Expected to Earn FY2017 Earnings of ($0.78) Per Share (ADMP)Adamis Pharmaceuticals Corporation Expected to Earn FY2017 Earnings of ($0.78) Per Share (ADMP)
www.americanbankingnews.com - November 17 at 8:00 AM
Relative Strength Alert For Adamis PharmaceuticalsRelative Strength Alert For Adamis Pharmaceuticals
www.thestreet.com - November 16 at 10:46 AM
 Adamis Pharmaceuticals Corporation (ADMP) Given $9.83 Average Target Price by Brokerages Adamis Pharmaceuticals Corporation (ADMP) Given $9.83 Average Target Price by Brokerages
www.americanbankingnews.com - November 14 at 1:50 AM
ETFs with exposure to Adamis Pharmaceuticals Corp. : November 9, 2017ETFs with exposure to Adamis Pharmaceuticals Corp. : November 9, 2017
finance.yahoo.com - November 9 at 4:25 PM
Financial Analysis: Adamis Pharmaceuticals Corporation (ADMP) & The CompetitionFinancial Analysis: Adamis Pharmaceuticals Corporation (ADMP) & The Competition
www.americanbankingnews.com - November 7 at 10:59 AM
ETFs with exposure to Adamis Pharmaceuticals Corp. : October 30, 2017ETFs with exposure to Adamis Pharmaceuticals Corp. : October 30, 2017
finance.yahoo.com - October 30 at 3:41 PM
Adamis Pharmaceuticals: Limited Risk, But Skeptical About Gains ... - Seeking AlphaAdamis Pharmaceuticals: Limited Risk, But Skeptical About Gains ... - Seeking Alpha
seekingalpha.com - October 28 at 3:41 AM
First Week Of ADMP June 2018 Options TradingFirst Week Of ADMP June 2018 Options Trading
www.thestreet.com - October 26 at 11:31 AM
Adamis Pharmaceuticals: A Rocket Counting Down To Lift-Off - Seeking AlphaAdamis Pharmaceuticals: A Rocket Counting Down To Lift-Off - Seeking Alpha
seekingalpha.com - October 25 at 4:16 PM
Adamis Pharmaceuticals: A ~$5 Biotech Stock That Should Sell For $10Adamis Pharmaceuticals: A ~$5 Biotech Stock That Should Sell For $10
seekingalpha.com - October 20 at 3:41 PM
ETFs with exposure to Adamis Pharmaceuticals Corp. : October 20, 2017ETFs with exposure to Adamis Pharmaceuticals Corp. : October 20, 2017
finance.yahoo.com - October 20 at 3:40 PM
Adamis Pharmaceuticals: Buy The Dip Ahead Of Symjepi Partnership And Launch - Seeking AlphaAdamis Pharmaceuticals: Buy The Dip Ahead Of Symjepi Partnership And Launch - Seeking Alpha
seekingalpha.com - October 19 at 3:52 PM
Adamis Pharmaceuticals Corporation (ADMP) Short Interest Down 37.5% in SeptemberAdamis Pharmaceuticals Corporation (ADMP) Short Interest Down 37.5% in September
www.americanbankingnews.com - October 14 at 2:04 AM
Adamis Pharmaceuticals Is Now Oversold (ADMP)Adamis Pharmaceuticals Is Now Oversold (ADMP)
www.thestreet.com - October 13 at 8:25 PM
ETFs with exposure to Adamis Pharmaceuticals Corp. : October 9, 2017ETFs with exposure to Adamis Pharmaceuticals Corp. : October 9, 2017
finance.yahoo.com - October 9 at 4:35 PM
Reviewing Astrazeneca PLC (AZN) and Adamis Pharmaceuticals Corporation (ADMP)Reviewing Astrazeneca PLC (AZN) and Adamis Pharmaceuticals Corporation (ADMP)
www.americanbankingnews.com - October 8 at 4:34 AM
Stock Performance Review on Drug Delivery Industry -- Adamis Pharma, Alkermes, PetMed Express, and Valeant PharmaStock Performance Review on Drug Delivery Industry -- Adamis Pharma, Alkermes, PetMed Express, and Valeant Pharma
www.bizjournals.com - October 5 at 12:25 PM
Cellectar Biosciences (CLRB) and Adamis Pharmaceuticals Corporation (ADMP) Financial ReviewCellectar Biosciences (CLRB) and Adamis Pharmaceuticals Corporation (ADMP) Financial Review
www.americanbankingnews.com - October 4 at 6:04 PM
Adamis Pharmaceuticals Corporation (ADMP) Receives New Coverage from Analysts at B. RileyAdamis Pharmaceuticals Corporation (ADMP) Receives New Coverage from Analysts at B. Riley
www.americanbankingnews.com - October 4 at 9:32 AM
ETFs with exposure to Adamis Pharmaceuticals Corp. : September 29, 2017ETFs with exposure to Adamis Pharmaceuticals Corp. : September 29, 2017
finance.yahoo.com - October 2 at 3:16 PM
ETFs with exposure to Adamis Pharmaceuticals Corp. : September 18, 2017ETFs with exposure to Adamis Pharmaceuticals Corp. : September 18, 2017
finance.yahoo.com - September 18 at 8:56 PM
Adamis Pharmaceuticals Corporation (ADMP) Now Covered by Raymond James Financial, Inc.Adamis Pharmaceuticals Corporation (ADMP) Now Covered by Raymond James Financial, Inc.
www.americanbankingnews.com - September 12 at 6:58 PM
ETFs with exposure to Adamis Pharmaceuticals Corp. : September 7, 2017ETFs with exposure to Adamis Pharmaceuticals Corp. : September 7, 2017
finance.yahoo.com - September 7 at 3:23 PM
ETFs with exposure to Adamis Pharmaceuticals Corp. : September 7, 2017ETFs with exposure to Adamis Pharmaceuticals Corp. : September 7, 2017
finance.yahoo.com - September 7 at 3:23 PM
Adamis Pharmaceuticals Corp. :ADMP-US: Earnings Analysis: Q2, 2017 By the Numbers : September 6, 2017Adamis Pharmaceuticals Corp. :ADMP-US: Earnings Analysis: Q2, 2017 By the Numbers : September 6, 2017
finance.yahoo.com - September 6 at 3:26 PM
Adamis Pharmaceuticals: Updates To Thesis - Seeking AlphaAdamis Pharmaceuticals: Updates To Thesis - Seeking Alpha
seekingalpha.com - August 27 at 1:29 AM
Adamis Pharmaceuticals Attempts To Extend 4-Day Winning StreakAdamis Pharmaceuticals Attempts To Extend 4-Day Winning Streak
www.benzinga.com - August 23 at 9:10 PM
Mylans Stock Is No Longer A Buy According To Analysts At Argus - BenzingaMylan's Stock Is No Longer A Buy According To Analysts At Argus - Benzinga
www.benzinga.com - August 22 at 9:02 PM
Adamis Pharmaceuticals Corporation (ADMP) Rating Reiterated by Maxim GroupAdamis Pharmaceuticals Corporation (ADMP) Rating Reiterated by Maxim Group
www.americanbankingnews.com - August 21 at 4:08 PM
Financial Review: Sanofi (SNY) versus Adamis Pharmaceuticals Corp (ADMP)Financial Review: Sanofi (SNY) versus Adamis Pharmaceuticals Corp (ADMP)
www.americanbankingnews.com - August 17 at 12:14 AM
Stonebridge Capital Advisors LLC Buys Gilead Sciences Inc, Microsoft Corp, SPDR S&P 500, ...Stonebridge Capital Advisors LLC Buys Gilead Sciences Inc, Microsoft Corp, SPDR S&P 500, ...
www.nasdaq.com - August 16 at 3:27 PM
Short Interest in Adamis Pharmaceuticals Corporation (ADMP) Drops By 36.7%Short Interest in Adamis Pharmaceuticals Corporation (ADMP) Drops By 36.7%
www.americanbankingnews.com - August 12 at 1:44 AM
Adamis Pharmaceuticals Corporation (ADMP) and Juniper Pharmaceuticals (JNP) Critical ReviewAdamis Pharmaceuticals Corporation (ADMP) and Juniper Pharmaceuticals (JNP) Critical Review
www.americanbankingnews.com - August 2 at 10:14 PM
Technical Reports on Drug Delivery Equities -- PetMed Express, Adamis Pharma ...Technical Reports on Drug Delivery Equities -- PetMed Express, Adamis Pharma ...
www.prnewswire.com - July 14 at 5:18 PM
ADMP Soars On FDA Nod, It Is Advantage OXFD, LLY In Good ... - NasdaqADMP Soars On FDA Nod, It Is Advantage OXFD, LLY In Good ... - Nasdaq
www.nasdaq.com - June 16 at 3:42 PM
Adamis Pharmaceuticals (ADMP) Announces FDA Approval for Epinephrine Pre-Filled SyringeAdamis Pharmaceuticals (ADMP) Announces FDA Approval for Epinephrine Pre-Filled Syringe
www.streetinsider.com - June 16 at 2:00 AM
ADMP Soars On FDA Nod, It Is Advantage OXFD, LLY In Good SpiritsADMP Soars On FDA Nod, It Is Advantage OXFD, LLY In Good Spirits
www.rttnews.com - June 16 at 2:00 AM
Health Care Sector Update for 06/15/2017: ADMP,SKLN,QBIO - NasdaqHealth Care Sector Update for 06/15/2017: ADMP,SKLN,QBIO - Nasdaq
www.nasdaq.com - June 15 at 8:50 PM
Adamis Pharmaceuticals (ADMP) Announces FDA Approval for Epinephrine Pre-Filled Syringe - StreetInsider.comAdamis Pharmaceuticals (ADMP) Announces FDA Approval for Epinephrine Pre-Filled Syringe - StreetInsider.com
www.streetinsider.com - June 15 at 8:50 PM
Adamis Pharmaceuticals: Strong Buy Before Huge Potential Catalyst ... - Seeking AlphaAdamis Pharmaceuticals: Strong Buy Before Huge Potential Catalyst ... - Seeking Alpha
seekingalpha.com - June 2 at 1:30 AM
Adamis Pharmaceuticals (ADMP) Prices 4.3M Shares at $3.50 - StreetInsider.comAdamis Pharmaceuticals (ADMP) Prices 4.3M Shares at $3.50 - StreetInsider.com
www.streetinsider.com - April 22 at 3:20 PM
Pre-Open Movers 04/21: (OCN) (VBLT) (PFPT) Higher; (XBIT) (ADMP) (EFII) (MAT) Lower (more...)Pre-Open Movers 04/21: (OCN) (VBLT) (PFPT) Higher; (XBIT) (ADMP) (EFII) (MAT) Lower (more...)
www.streetinsider.com - April 21 at 8:20 PM
Mid-Day Market Update: CAI International Gains On Strong Results; Adamis Pharmaceuticals Shares Slide - NasdaqMid-Day Market Update: CAI International Gains On Strong Results; Adamis Pharmaceuticals Shares Slide - Nasdaq
www.nasdaq.com - April 21 at 3:19 PM
Adamis Pharmaceuticals (ADMP) to Offer Common Stock - StreetInsider.comAdamis Pharmaceuticals (ADMP) to Offer Common Stock - StreetInsider.com
www.streetinsider.com - April 21 at 3:19 PM
ADAMIS PHARMACEUTICALS CORP Files SEC form 10-K, Annual ReportADAMIS PHARMACEUTICALS CORP Files SEC form 10-K, Annual Report
biz.yahoo.com - March 30 at 8:46 PM
Is the Options Market Predicting a Spike in Adamis Pharmaceuticals (ADMP) Stock? - NasdaqIs the Options Market Predicting a Spike in Adamis Pharmaceuticals (ADMP) Stock? - Nasdaq
www.nasdaq.com - February 27 at 3:29 PM

Social Media

Financials

Chart

Adamis Pharmaceuticals Corporation (NASDAQ ADMP) Chart for Saturday, November, 25, 2017
Loading chart…

This page was last updated on 11/25/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.